Clinical trial
Real-time Early Detection of Nephrotoxicity by Accurate and Faster Urinary Biomarker Analysis With SeroFlow Technology (RenaFAST Study)
NCT06124885 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-time Early Detection of Nephrotoxicity by Accurate and Faster Urinary Biomarker Analysis With SeroFlow Technology (RenaFAST Study)
- Lead sponsor
- National University Hospital, Singapore
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- November 30, 2023
- Completion date
- December 31, 2024
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.